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N-methyl-D-aspartate receptor (NMDAR) excitotox-
icity is implicated in the pathogenesis of Hunting-
ton’s disease (HD), a late-onset neurodegenerative
disorder. However, NMDARs are poor therapeutic
targets, due to their essential physiological role.
Recent studies demonstrate that synaptic NMDAR
transmission drives neuroprotective gene transcrip-
tion, whereas extrasynaptic NMDAR activation pro-
motes cell death. We report specifically increased
extrasynaptic NMDAR expression, current, and
associated reductions in nuclear CREB activation in
HD mouse striatum. The changes are observed in
the absence of dendritic morphological alterations,
before and after phenotype onset, correlate with
mutation severity, and require caspase-6 cleavage
of mutant huntingtin. Moreover, pharmacological
block of extrasynaptic NMDARs with memantine
reversed signaling and motor learning deficits. Our
data demonstrate elevated extrasynaptic NMDAR
activity in an animal model of neurodegenerative
disease. We provide a candidate mechanism linking
several pathways previously implicated in HD patho-
genesis and demonstrate successful early thera-
peutic intervention in mice.
INTRODUCTION
NMDAR activity is imperative for vital brain functions, including
synaptic plasticity, gene transcription, and cell survival (Bliss
and Collingridge, 1993; Hardingham and Bading, 2003);
however, overactivation of these receptors causes calcium over-
load and subsequent cell death (Arundine and Tymianski, 2003).178 Neuron 65, 178–190, January 28, 2010 ª2010 Elsevier Inc.Evidence suggests that excessive NMDAR activity contributes
to the pathogenesis of Huntington’s disease (HD), a disorder
characterized by degeneration of striatal medium-sized spiny
neurons (MSNs; reviewed in Cowan and Raymond, 2006). Yet
cognitive and psychiatric disturbances occur in HD gene carriers
years before onset of motor symptoms or classical neuropa-
thology (Duff et al., 2007; Solomon et al., 2007). Notably,
NMDAR-dependent plasticity and transmission are altered in
HD transgenic mice months prior to onset of motor deficits
(Andre et al., 2006; Cepeda et al., 2001a; Li et al., 2004; Milner-
wood et al., 2006; Milnerwood and Raymond, 2007; Van Raams-
donk et al., 2005), NR2B-containing NMDARs show increased
surface expression, current, and toxicity in MSNs from HD
mice (Fan et al., 2007; Shehadeh et al., 2006), and NR2B overex-
pression enhances striatal neuronal loss in HD mice (Heng et al.,
2009). NMDARs are therefore an attractive candidate target for
therapeutic intervention in HD. However, as these receptors
are critical to many processes, broad intervention of NMDAR
activity produces serious side effects (Chen and Lipton, 2006).
Neuronal culture studies demonstrate that the consequences
of NMDAR activity are determined by the subcellular location of
the receptor (reviewed in Hardingham and Bading, 2003; Ko¨hr,
2006). A dichotomy between synaptic and extrasynaptic activity
determines whether resulting signaling is beneficial (prosurvival)
or detrimental (cell death pathways); synaptic activation pro-
motes CREB phosphorylation, BDNF transcription, ERK activa-
tion, and antioxidant defense, whereas extrasynaptic signaling
opposes synaptic signaling pathways in a dominant manner,
leading to dendritic blebbing, mitochondrial breakdown, and
cell death (Gouix et al., 2009; Hardingham et al., 2002; Leveille
et al., 2008; Papadia et al., 2008). However, evidence for
increased extrasynaptic NMDAR transmission in genetic models
of human diseases has been lacking.
Here we present evidence indicating increased NR2B-con-
taining extrasynaptic NMDARs in the striatum of transgenic
mice expressing mutant full-length human huntingtin (htt) pro-
tein. Augmented extrasynaptic NMDAR signaling is detected at
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more, HD mice treated with an NMDAR antagonist that preferen-
tially targets extrasynaptic current (Leveille et al., 2008; Okamoto
et al., 2009; Papadia et al., 2008) showed reversal of early
nuclear signaling and motor learning deficits. The data provide
a candidate mechanism for both early synaptic dysfunction, pre-
dicted to underlie cognitive deficits, and the delayed neuropa-
thology observed in HD.
RESULTS
Yeast artificial chromosome (YAC) constructs are used to
express the full human htt gene and its regulatory elements
with normal (18) or pathological (72 or 128) CAG repeats in
FVB/N mice. Similarly to human disease, YAC72/128 mice
exhibit delayed neurodegeneration after cognitive and motor
deficits (Hodgson et al., 1999; Slow et al., 2003; Van Raamsdonk
et al., 2005). NMDAR activity is increased in MSNs from
presymptomatic YAC72 and YAC128 mice (Fan et al., 2007; Mil-
nerwood and Raymond, 2007; Zhang et al., 2008), and in
cultured MSNs, mutant htt (mhtt) perturbs NMDAR surface traf-
ficking (Fan et al., 2007). To assay NMDAR localization in MSNs
of an intact network, we recorded evoked and spontaneous
excitatory postsynaptic currents (e/sEPSCs) in acute slices
using standard patch-clamp techniques (Milnerwood and Ray-
mond, 2007). With the aim of developing strategies to prevent
onset and progression of HD, we centered investigations on
presymptomatic 1-month-old mice.
Strong Synaptic Stimulation Reveals Enhanced NMDAR
Activity
In conditions designed to promote NMDAR activity at near-
resting membrane potentials (70 mV, low Mg2+ aCSF: 5 mM
Mg2+, 20 mM glycine), we evoked EPSCs (eEPSCs; local afferent
stimulation) mediated by both NMDA and AMPA receptors
(AMPAR), herein ‘‘dual’’ EPSCs. Evoked input-output curves
showed no significant differences in dual eEPSC peak or charge
between YAC18 and YAC128 MSNs (Figure S1). However,
eEPSC charge relative to response peak increased with esca-
lating stimulation, an effect more pronounced in YAC128
MSNs (Figure 1A, two-way ANOVA genotype p = 0.002, F1,157 =
9.79), significantly at high stimulation levels only (Mann-Whitney t
test 250 mA p = 0.03). The data suggest that elevated NMDAR
current in mhtt MSNs is only apparent in the slice at high levels
of glutamate release and consequent spillover (Arnth-Jensen
et al., 2002; Lozovaya et al., 2004; Scimemi et al., 2004). To
directly test this, paired-pulse stimuli were delivered to increase
presynaptic release (Figure 1B). Paired dual eEPSCs were
recorded in the absence, then presence, of the NMDAR antago-
nist D-AP5, allowing calculation of INMDA by subtracting residual
AMPAR current from initial AMPAR/NMDAR-mediated currents
(Thomas et al., 2000).
Evoked field potential and AMPAR current amplitudes were
not significantly different between YAC18 and YAC128 MSNs
(Figure S1). In contrast, INMDA peak (Figure S1) and charge
area were significantly elevated in YAC128 MSNs (Figure 1Bii,
RM-ANOVA genotype p = 0.006, F1,22 = 9.13; interaction p =
0.013, F1,22 = 7.31), the source being significantly increasedINMDA charge in YAC128 MSNs at high stimulation intensity.
Relative charge (INMDAC/IAMPA peak) was also increased in
YAC128 MSNs (genotype p = 0.015, F1,22 = 6.89). Direct compar-
isons revealed the source to be significant increases at high
stimulation in the second (P2, facilitated) response. The results
demonstrate that, in response to paired presynaptic stimuli,
INMDA is 2- to 3-fold greater in YAC128 MSNs. Thus, augmented
NMDAR activity is more readily observed with high levels of
presynaptic release.
No Effect of Mutant htt on Spontaneous Synaptic
NMDAR Activity
We also assayed INMDA at lower levels of presynaptic activity, as
occur with spontaneous release (sEPSCs). In our coronal prepa-
ration, >90% of sEPSCs are action potential (AP) independent
and likely due to spontaneous vesicle release (Figure S2); thus,
sEPSC INMDA should represent NMDARs active directly under
the release site, at the postsynaptic density (Figure 1Ci). INMDA
was quantified in sEPSCs by subtractive calculation from dual
currents (70 mV, low Mg2+ aCSF). Strikingly, in the same cells
that exhibited 2- to 3-fold increases in YAC128 NMDAR-medi-
ated eEPSCs (with paired stimulation), YAC18 and YAC128
sEPSCs showed similar INMDA charge, relative charge (Figures
1Cii–1Civ), and decay constants (Figure S1). To investigate
synaptic INMDA in standard ACSF (2 mM Mg
2+), we also
unmasked INMDA by membrane depolarization (Figure 1D). Slow-
ing of sEPSC decay constants was D-AP5 sensitive, and sEPSC
decay measured at 20 mV was similar across all genotypes.
In contrast to paired-stimulus-evoked eEPSCs, sEPSCs may
be biased toward a heterogeneous high probability of release
(Pr) input pathway with a decreased NMDAR:AMPAR ratio, i.e.,
thalamostriatal versus corticostriatal inputs (Ding et al., 2008).
If so, elevated INMDA in YAC128 paired-pulse eEPSCs may be
attributable to increased contribution from corticostriatal con-
nections; however, the high Pr thalamostriatal pathway has else-
where been reported to exhibit an increased NMDAR:AMPAR
ratio relative to the corticostriatal pathway (Smeal et al., 2008).
In order to address such potential confounds, we increased
Pr with the K+ channel blocker 4-aminopyridine (4-AP, 100 mM,
Cepeda et al., 2001b). This drug had no effect upon mEPSC
frequency (Figure S2) but dramatically increased AP-dependent
release (>4-fold increase in sEPSC frequency, Figure 2). Simi-
larly to Figures 1B and 1C, we recorded before and after
NMDAR block to calculate INMDA in mean events generated
by sampling individual, large AP-dependent sEPSCs (detection
threshold >35 pA). The mean amplitude and frequency of AP-
dependent sEPSCs were indistinguishable (71.7 ± 4.7 pA,
65.1 ± 3.8 pA p = 0.25 and 7.2 ± 1.8 Hz, 6.6 ± 1.3 Hz
p = 0.82 for YAC18 and YAC128, respectively) and subtracted
INMDA peak, charge, and normalized charge were also similar
between genotypes.
We also ruled out potential bias introduced by event sampling
that may filter out important NMDAR activity, such as slow
currents carried by NMDARs at AMPAR-silent synapses that
lack sharp activation kinetics used to detect events. All-point
histograms of 1 min sweeps in the absence and presence of
NMDAR block were generated and group means compared
(Figure 2iii). Such plots quantify both tonic (Gaussian fit) andNeuron 65, 178–190, January 28, 2010 ª2010 Elsevier Inc. 179
Figure 1. NMDAR Currents Are Increased in YAC128 MSNs but Only with High Levels of Presynaptic Release
(A) Dual AMPAR and NMDAR-mediated evoked EPSCs (eEPSCs,70 mV low Mg2+) produced by local glutamatergic afferent stimulation exhibit increased rela-
tive charge with increasing stimulus intensity (top left: Ai, Aii, Aiii = 100, 150, and 250 mA; top right: peak normalized); slowing is indicative of increased NMDAR
contribution. YAC128 relative charge is greater with high-intensity stimulation (bottom).
(Bi) Cartoon depicting paired-pulse stimulation of afferents (strikes) resulting in high levels of action potential (AP)-dependent release at many synapses (top). Dual
AMPA/NMDA-mediated eEPSCs in low Mg2+ (gray), +D-AP5 (IAMPA, black). IAMPA was subtracted from dual to give INMDA (fill). (Bii and Biii) INMDA charge (Bii) and
relative charge (normalized to IAMPA; Biii) are significantly increased in YAC128 (p, one-tailed t test).
(C) Cartoon depicting low-level spontaneous activity (Ci); AP-independent release occasionally occurs at single synapses, generating small sEPSCs (20 pA,
2–3 Hz postsynaptically). Currents quantified as in (Bi); average sEPSC INMDA charge and relative charge (Cii–Civ; same cells as in B) are similar between geno-
types.
(D) In standard aCSF, spontaneous currents (sEPSCs) have slower decay constants at20 than70 mV (Di and Dii), DTau (D-AP5-sensitive; INMDA-mediated) is
similar across genotypes.
Data expressed as mean ± SEM.
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(Glykys and Mody, 2007). There were no significant differences
in dual or IAMPA plots between genotypes, nor were there signif-
icant differences between genotypes in the magnitude of the
NMDAR-dependent component.
The absence of any increase in sEPSC INMDA, even within large
single events, together with 2- to 3-fold increased INMDA in large
paired-pulse eEPSCs, suggests that elevated YAC128 INMDA is
produced by glutamate spillover and activation of NMDARs
outside the influence of individual release events, at peri- and/or
extrasynaptic locations (Lozovaya et al., 2004).
Increased Extrasynaptic NMDAR Activation Unmasked
by Augmented Glutamate Spillover
Precise connections between neurons are essential for discrete
transmission, and synaptic fidelity is maintained by the action of
glutamate uptake transporters on neurons and glia. In order to180 Neuron 65, 178–190, January 28, 2010 ª2010 Elsevier Inc.generate spillover to extrasynaptic receptors, we evoked iso-
lated NMDAR EPSCs (standard aCSF, +60 mV, 10 mM CNQX)
before and during application of the non-pump-reversing
GLT-1 glutamate transport inhibitor DL-TBOA (10 mM, Figure 3A).
TBOA promotes diffusion of glutamate from release sites and
activation of NMDARs beyond the synaptic sphere of influence
(Tzingounis and Wadiche, 2007).
In TBOA, NMDAR eEPSC kinetics slowed (Figure 3), in agree-
ment with hippocampal studies (Arnth-Jensen et al., 2002; Sci-
memi et al., 2004). TBOA effects were reversible, and 88% ±
6% (n = 5) of eEPSC charge in TBOA was eliminated by D-AP5
(Figure 3Aiii). Slowing of INMDA was modest in WT and YAC18,
occasionally pronounced in YAC72, and consistently pro-
nounced in YAC128 MSNs. Both YAC128 INMDA TauW and
peak normalized charge were significantly greater than WT or
YAC18, with YAC72 showing intermediate values (Figure 3B,
two-way RM-ANOVA interaction: TauW p = 0.01, F4,62 = 3.5,
Figure 2. With Elevated Pr, sEPSC and Tonic INMDA Are Similar
(A) After increasing Pr (100 mm 4-AP), NMDAR activity was assessed by NMDAR block (right; 5 mM L689,560).
(B) AP-dependent dual sEPSCs (>30 pA) were averaged for each cell as in Figures 1B and 1C; there were no differences in INMDA peak, charge, or relative charge
(following peak normalization, right) between genotypes.
(C) To avoid event sampling bias, all-point histograms ±INMDA were produced for each cell, and group means were compared to quantify both tonic (Gaussian fit)
and phasic (negative shift from Gaussian) glutamatergic activity (expanded top right). Dual INMDA/IAMPA and IAMPA current distributions (top and bottom left) were
similar between genotypes, as was the difference between the two histograms within genotype (INMDA). Bottom right: expanded dual INMDA/IAMPA plot shows that
phasic INMDA activity is not increased, but reduced in YAC128s.
Data expressed as mean ± SEM, excepting whisker plots in (B).
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The data suggest extrasynaptic INMDA (Ex-INMDA) charge transfer
was 2- to 3-fold increased in YAC128, and increased intermedi-
ately in YAC72, MSNs. Consistent with these findings, TBOA
also increased the holding current (Ihold), a portion of which is
NMDAR-dependent (Le Meur et al., 2007). NMDAR-dependent
increases in Ihold over the first 5 min of TBOA exposure were
significantly greater in YAC128 MSNs (Figure S3). Thus, the
results of TBOA exposure are also consistent with a mhtt-depen-
dent increase in the number, or activity, of extrasynaptic
NMDARs.Elevated Extrasynaptic NMDAR Signaling Requires
Caspase-6 Cleavage of mhtt
There is considerable evidence for caspase cleavage of htt in HD
pathogenesis (Wellington et al., 2000). Notably, C6R mice
express a construct identical to YAC128 mice, excepting a point
mutation rendering mhtt resistant to caspase-6 cleavage. C6R
mice are resistant to the excitotoxicity, neurodegeneration, and
behavioral characteristics of YAC128 mice (Graham et al.,
2006a; Pouladi et al., 2009), strongly arguing that mhtt proteol-
ysis is required for the formation of toxic htt fragments. However,
electrophysiological investigation of C6R mice has not previ-
ously been presented. Here, we found that C6R MSNs were
remarkably similar to YAC18 and WT MSNs; increases in INMDAdecay, charge, and Ihold following TBOA application were
modest and significantly different from YAC128 MSNs (Figures
3B and S3). The data suggest that caspase-6 cleavage of mhtt
is necessary for increased Ex-INMDA, subsequent behavioral
deficits, excitotoxicity, and neurodegeneration.
Elevated Ex-INMDA Occurs Independently of Synaptic
NMDAR Activation
To further characterize Ex-INMDA, we ruled out the possibility that
increased INMDA in TBOA may be attributable to modulation of
synaptic NMDARs. Following blockade of synaptic INMDA with
the use-dependent, irreversible antagonist MK-801 and subse-
quent washout, we found that TBOA resulted in a highly signifi-
cant elevation of Ex-INMDA in YAC128 MSNs (Figure 4). Notably,
concomitant IAMPA and field potentials were reduced, indicating
that TBOA did not increase glutamate release. The data demon-
strate that elevated YAC128 INMDA is not carried by altered
synaptic responses.
Elevated Ex-INMDA without Dendritic Morphological
Alteration and Persistence with Age
Differential synaptic development or other alterations to MSN
morphology already present at 1 month may contribute to the
observed increased Ex-INMDA. However, Golgi impregnation
and 3D reconstruction of YAC18 and YAC128 MSNs revealedNeuron 65, 178–190, January 28, 2010 ª2010 Elsevier Inc. 181
Figure 3. Glutamate Transport Block,
Increased Spillover, and Elevated Extrasy-
naptic NMDAR Activity in YAC128 MSNs
(Ai) Cartoon depicting increased glutamate diffu-
sion from the synaptic cleft following stimulation
in the absence of glial glutamate reuptake. (Aii)
Representative isolated NMDAR eEPSCs (stan-
dard aCSF, +60 mV, 10 mM CNQX top, peak
scaled below) showing pronounced slowing of
INMDA by DL-TBOA (10 mM TBOA, 10 min). (Aiii)
Slower eEPSCs in TBOA are entirely NMDAR
mediated; peak and charge are much reduced
by AP5 (paired t test).
(B) Top: TBOA produces a significantly greater
slowing of YAC128 INMDA that is entirely reversible
(see text). Bottom: INMDA charge (peak scaled) is
significantly increased in YAC128s following
TBOA application (two-way RM-ANOVA Bonfer-
roni post hoc).
Data expressed as mean ± SEM.
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endpoints, branching, total length, or spine densities between
genotypes (Figure 5A).
To determine whether elevated Ex-INMDA is observed in aged
mice, after phenotype onset, we recorded in slices from mice
aged >1 year. Although at 12 months YAC128 mice show 18%
striatal cell loss (Slow et al., 2003), all surviving cells exhibited
inward rectification characteristic of MSNs and membrane prop-
erties indistinguishable from age-matched WT littermates
(Figure 5B). As at 1 month, at R1 year eEPSC relative charge
was increased, but only at high stimulus intensities (two-way
RM ANOVA interaction p = 0.04, F2,22 = 3.6, direct comparison
MW t test), and TBOA resulted in significantly increased
Ex-INMDA (two-way RM ANOVA interaction p = 0.03, F1,6 = 7.7,
direct comparison MW t test).
Aside from alterations to MSN morphology, a loss of glial
contacts could also produce increased glutamate diffusion and
elevated Ex-INMDA. Ultrastructural assessment (Figure 5C)
revealed no difference between WT and YAC128 (p = 0.5, 0.76 ±
0.06, 0.82 ± 0.04, respectively) in the proportion of asymmetric
synapses with contacting astrocytes, and there were no differ-
ences in the distance between astrocytic processes and the
postsynaptic density (PSD, p = 0.07, 70.8 ± 6.6 and 83.4 ±
6.9 nm).
Elevated Ex-INMDA Is NR2B Dependent
In order to avoid other potential developmental confounds, at
1 month we assayed YAC128 versus WT littermates. Further,
we increased the concentration of TBOA (from 10 to 30 mM,182 Neuron 65, 178–190, January 28, 2010 ª2010 Elsevier Inc.also see Figure 4), to control for differ-
ences in transporter efficacy. As before,
eEPSC relative charge was significantly
increased in YAC128 MSNs only at high
stimulus intensities (Figure 6A, two-way
ANOVA genotype p = 0.009, F1,63 = 7.1,
direct comparison t test). Transient
TBOA application (30 mM) led to a fullyreversible 50% increase in WT INMDA, in contrast to a 125%
increase in YAC128 INMDA (Figures 6B and 6C, two-way
ANOVA genotype p = 0.0001, F1,60 = 34.6, Boferroni post hoc),
demonstrating that deficits in transporter efficacy are unlikely
to underlie augmented Ex-INMDA in YAC128 mice.
Next we investigated a role for NR2B-type NMDARs and
mGluRs in elevated Ex-INMDA. The NR2B NMDAR subunit-
selective antagonist ifenprodil (10 mM; Williams, 2001) produced
small reductions in INMDA peak in both WT and YAC128
MSNs (Figure 6D, 16.7% ± 4.3% p = 0.01 and 19.7% ± 3.4%
p = 0.02, respectively, paired t test). Upon subsequent tran-
sient application of TBOA, ifenprodil eliminated the difference
between YAC128 and WT INMDA decay TauW (Figures 6E and
6F, p = 0.6). Contrastingly, the broad spectrum group I/II
mGluR antagonist S-MCPG (250 mM; Sergueeva et al., 1993)
had no significant effect upon TBOA-induced increase in
Ex-INMDA TauW in WT or YAC128 MSNs (Figure 6F), demon-
strating that mGluR activity is not required. Collectively, the
data suggest that elevated Ex-INMDA in YAC128 MSNs is carried
by a distinct extrasynaptic population of NR2B-containing
NMDARs.
Altered Subcellular Localization of NMDAR Subunits
To determine whether synaptic NMDAR trafficking is altered by
mhtt expression, we investigated subunit localization by frac-
tionation of synaptosomes (Pacchioni et al., 2009). Synapto-
some preparations contain pre- and postsynaptic structures
(reviewed in Whittaker, 1993); including endosomal, perisynap-
tic, extrasynaptic membranes, and the specialized postsynaptic
Figure 4. Block of Synaptic INMDA and
Elevated TBOA-Induced Ex-INMDA in
YAC128 MSNs
(A) MK-801 (5mM) irreversibly blocked INMDA
components of ‘‘dual’’ eEPSCs (Ai and Aii), while
preserving IAMPA (for assessment of preparation
stability).
(B and C) After a period of quiescence for MK801
wash-out, irreversible block is demonstrated by
persistent loss of slow INMDA (ii, IAMPA persists; B
and C, last datum renormalized). Application of
TBOA (30 mM, 10 min) results in re-emergence
and augmentation of INMDA upon resumption of
test shocks (iii), reflecting peri/extrasynaptic
NMDAR activity (Ex-INMDA). This reversible effect
is significantly greater in YAC128s (second
through fourth shocks upon resumption, two-
way ANOVA genotype p = 0.0005 F2,39 = 14.3).
(D) YAC128 relative INMDA charge is >2-fold
increased following peak (IAMPA) normalization to
account for reductions in presynaptic release,
suggested by subtle alterations in fields and IAMPA
peak (B and C).
(E) Quantification of first and next nine averaged
responses after resumption of stimulation in
TBOA in (D); YAC128 relative charge was signifi-
cantly increased (Mann Whitney t tests; first
response p = 0.007, 2–10 average p = 0.005).
Data expressed as mean ± SEM, except for the
whisker box plots in (E).
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insoluble ‘‘PSD-enriched’’ membrane fraction and a ‘‘non-PSD
enriched’’ membrane fraction, which includes extrasynaptic
plasma membrane receptors (Figure 7A). A clear separation of
PSD and non-PSD membranes was achieved, as demonstrated
by the distribution of PSD-95, synaptophysin, calnexin, and
Rab5 (Figures 7A and S4). NR1, NR2A, and NR2B immunoreac-
tivity was significantly increased in YAC128 striatal ‘‘non-PSD’’
fractions with respect to YAC18 (12.5 ± 4.9 p = 0.01, 15.5 ±
3.4 p = 0.03, and 48.3% ± 13.2% p = 0.002, respectively,
Wilcoxon SR test; Figure 7A). All three subunits were also
decreased in the synaptic ‘‘PSD’’ fraction, although this reduc-
tion only reached significance for NR2B (15.5% ± 5.0%
p = 0.02). A similar pattern was also observed in non-PSD
fractions from cortical tissue, with significant increases in NR1
and NR2B subunits (12.5 ± 4.8 p = 0.02 and 59.6% ± 30.1%
p = 0.02, respectively). Unlike the striatum, there were no reduc-
tions in NMDAR subunit immunoreactivity in cortical PSD
fractions.Memantine Treatment Restores CREB Activation
and Motor Learning
The mislocalization of NMDAR subunits to peri- and extrasynap-
tic membranes and associated increases in Ex-INMDA would be
predicted to dominantly oppose synaptic NMDAR nuclear
signaling, reducing CREB activation (Hardingham et al., 2002).
We therefore assayed basal CREB activity in nuclear fractions
of YAC18 and YAC128 striatum from mice aged 1 month(Figure 7B). As predicted, there was significantly less nuclear
CREB activity in YAC128 striatum (p = 0.04 MW t test).
Remarkably, in a recent study low-dose treatment with the
weak NMDAR antagonist memantine from 2 months reversed
neuropathological and behavioral deficits in YAC128 mice
when assessed at 12 months (Okamoto et al., 2009). Further-
more, high-dose memantine was detrimental to YAC128 mice,
consistent with in vitro observations demonstrating that low-
dose memantine preferentially antagonizes deleterious extrasy-
naptic NMDAR activity and signaling (Leveille et al., 2008; Oka-
moto et al., 2009; Papadia et al., 2008). We compared nuclear
CREB activity in the striatum of 4-month-old WT and YAC128
mice with YAC128 mice that received 1 mg/kg (low dose) mem-
antine from 2 months (Figure 8A). There were significant effects
of genotype and treatment, due to the predicted reduction in
nuclear CREB activation in the YAC128 striatum versus WT
controls, and a striking reversal of this early deficit in the meman-
tine-treated mice.
At 2–4 months of age, although free of obvious motor dysfunc-
tion, YAC128 motor learning is impaired, as evidenced by
increased failures (number of falls) when learning the rotarod
test (Van Raamsdonk et al., 2005). Here, we observed similar
results and, in addition to reversing the CREB signaling deficit,
memantine treatment significantly reversed this early motor
learning deficit (Figure 8B). These data add to the previous report
of rescue of motor function in YAC128 at 12 months of age
(Okamoto et al., 2009) and demonstrate that appropriate early
therapeutic intervention produces a significant alleviation of
phenotype onset and progression of HD.Neuron 65, 178–190, January 28, 2010 ª2010 Elsevier Inc. 183
Figure 5. Elevated Ex-INMDA Is Not Attributable to Altered Morphology or Reduced Glial Contact and Persists in Aged YAC128s
(A) Golgi impregnation of 1 month YAC18 and YAC128 brains. Top: 3D cell reconstruction and Sholl analysis demonstrated no significant differences in MSN
morphology (YAC18 n = 20, YAC128 n = 19). Bottom: Photomontage and example of 3D reconstructed spines (left); densities were similar between genotypes
in 1, 2, 3, and 4 dendrites (YAC18 n = 13, YAC128 n = 13).
(B) WC patch recordings in YAC128 (filled) and aged-matched wild-type littermates (clear) atR1 year. Left: Passive membrane properties assayed by current-
clamp I/V demonstrated that all cells targeted exhibited inward rectification (WT n = 7, YAC128 n = 5). Middle: Dual eEPSCs (standard aCSF, +60 mV) shows
increased relative eEPSC charge in YAC128 MSNs at high stimulus intensities only (WT n = 7, YAC128 n = 7). Right: Isolated NMDAR eEPSC (+60 mV,
10 mM CNQX) decay TauW before and after glutamate transport block (10 mM TBOA, 10 min) producing Ex-INMDA activity (DINMDA decay) that was significantly
increased in YAC128s (WT n = 4, YAC128 n = 4, two-way RM ANOVAs, MW t tests).
(C) Electron Microscopy at 1 year. Left: Representative electron micrograph showing two striatal synapses and contacting astrocyte processes (bar = 500 nm,
shaded: perisynaptic astrocyte processes, line: postsynaptic density delineated). Right: There were no differences in the proportion of synapses with astrocyte
contacts per 100 mm2 or the distance between the PSD and astrocytic processes between aged-matched wild-type littermates and YAC128 brains (WT n = 3 mice
92 synapses, YAC128 n = 3 mice 107 synapses).
Data expressed as mean ± SEM, except for the whisker box plots in (A).
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Previous investigations in HD mice have demonstrated that mhtt
expression alters NMDAR function from the earliest stages of
disease (reviewed in Cepeda et al., 2007; Fan and Raymond,
2007). Some of the observed perturbations in NMDAR activity
would be detrimental to neuronal function (Milnerwood et al.,
2006; Milnerwood and Raymond, 2007; Milnerwood and Ray-
mond, 2006; Murphy et al., 2000; Wolf et al., 2005) and adversely
impact neuronal survival (Graham et al., 2006a, 2006b; Sheha-
deh et al., 2006; Zeron et al., 2002, 2004).
Here we demonstrate that NMDAR current in YAC128 MSNs is
similar to WT and YAC18 controls when produced by low or
moderate levels of synaptic activity, but increased at high levels.
The NMDAR components of mEPSCs, large AP-dependent
sEPSCs, and even low-stimulus-intensity eEPSCs were all
similar between YAC128 and control mice. Elevations in
YAC128 INMDA were only apparent with high levels of synchro-
nously released glutamate from many synapses. Specifically,
small increases were observed with high stimulation intensities
(driving release from a large number of inputs), and large
increases were revealed by paired stimuli driving facilitated184 Neuron 65, 178–190, January 28, 2010 ª2010 Elsevier Inc.release at many individual synapses. This suggests that spillover
of glutamate to extrasynaptic sites is required to unmask
augmented INMDA in YAC128 MSNs. In agreement with this,
blockade of glutamate transporters and individual stimuli
revealed similarly large increases in YAC128 INMDA. These results
indicate that expression of full-length mhtt enhances NMDAR
current outside synapses, shifting the balance of synaptic:extra-
synaptic NMDAR activity.
Altered NMDAR Trafficking and Excitotoxicity
Elevated Ex-INMDA in YAC128 MSNs was abolished by NR2B-
type NMDAR selective blockade, and although NR1, NR2A,
and NR2B subunits all showed a shift from synaptic to nonsy-
naptic membranes, by far the largest effect was on NR2B
subunits. Together the data strongly suggest that mhtt results
in the expression of a distinct population of NR2B-containing
extrasynaptic NMDARs. Although we have not addressed the
mechanism of NMDAR mislocalization here, we have demon-
strated elsewhere that calpain activity levels are elevated in
YAC HD MSNs (Cowan et al., 2008). Calpain activity cleaves
the C-terminal region of NR2B NMDAR subunits, resulting
in functional membrane-bound receptors lacking regulatory
Figure 6. Ex-INMDA Is Not Due to Decreased
Uptake and Is Mediated by NR2B Subunit-
Containing NMDAR
(A) Dual eEPSCs (standard aCSF, +60 mV) show
increased relative eEPSC charge in YAC128
MSNs at high stimulus intensities only (YAC128
n = 10 filled versus WT n = 13 clear).
(B) Transient exposure of isolated NMDAR
eEPSCs (+60 mV, 10 mM CNQX) to 30 mM TBOA
(5 min) produced Ex-INMDA activity (DINMDA relative
charge) that was significantly greater in YAC128s
(two-way RM AVOVA, WT n = 9 YAC128 n = 13).
(C) Summary of TBOA effects; percent changes in
charge, relative charge, and decay TauW were
significantly increased in YAC128 MSNs (two-
way ANOVA, Bonferroni post hoc).
(D) Ifenprodil significantly reduced isolated
NMDAR eEPSC peaks to an equal extent in both
genotypes (WT n = 5, YAC128 n = 4).
(E) The increase in decay TauW produced by TBOA
(group data as in top right) was not significantly
different between genotypes in the presence of
ifenprodil (10 mM, WT n = 3, YAC128 n = 4).
(F) Summary data of INMDA decay TauW before and
during 30 mM TBOA alone or in the presence of ifen-
prodil (10mM) or s-MCPG(250mM WT n = 3 YAC128
n = 3, one-way ANOVA, Bonferroni post hoc).
Data expressed as mean ± SEM.
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Increased Extrasynaptic NMDARs in HD MiceC-terminal tails (Wu et al., 2007) responsible for synaptic versus
extrasynaptic localization (Prybylowski et al., 2005). Thus,
elevated calpain activity may contribute to increased extrasy-
naptic (NR2B-containing) NMDARs.
Previous work demonstrates that HD striatal neurons in vivo
and culture are more sensitive to NMDAR excitotoxicity. Intra-striatal injection of the NMDAR agonist quinolinic acid pro-
duces a significantly larger lesion in YAC128 versus WT
mice at 3 months (Graham et al., 2006a), consistent with an
increased proportion of extrasynaptic compared with syn-
aptic activity in YAC128 striatum, as shown here. In neuronal
culture, both YAC72 and YAC128 MSNs are hypersensitive toFigure 7. Altered NMDAR Subunit Localiza-
tion and Reduced CREB Signaling
(A) Model of fractionation protocol; synaptosomes
are digested to yield Triton-X-insoluble PSD-en-
riched (PSD) and -soluble non-PSD enriched
(non-PSD) fractions, corresponding to synaptic
versus peri-/extrasynaptic and presynaptic mem-
branes (left). Representative blots showing sepa-
ration of PSD and non-PSD fractions in striatal
(S) and cortical (C) synaptosomes from YAC18
and YAC128 mice; as demonstrated by PSD-95
and synaptophysin separation (middle). Fractions
were probed for NR1, NR2A, and NR2B subunit
alterations in YAC128 mice (NR1 n = 10, NR2A
n = 5, NR2B n = 11 relative to paired YAC18);
NR1, NR2A, and NR2B subunit immunoreactivity
(relative to actin) were significantly increased in
non-PSD fractions from YAC128 striatum. Signifi-
cant reductions in NR2B were also observed in
striatal PSD ‘‘synaptic’’ fractions. NR1 and NR2B
were also significantly elevated in non-PSD
fractions from cortex, yet no alterations were
observed in the PSD (Wilcoxon SR t test).
(B) Nuclear fractionation was confirmed by
HDAC1 immunoreactivity and striatal samples
were probed for CREB and pCREB (representative
blots left). Basal CREB activation was significantly
reduced in YAC128 striatum at 1 month (MW t test).
Data expressed as mean ± SEM (A) and whisker
box plot (B).
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Figure 8. CREB Activation and Motor Learning Deficits Are
Reversed by Memantine Treatment
(A) At 4 months, nuclear CREB activity (representative blots left) is significantly
reduced in YAC128 striatum. Memantine treatment from 2 months significantly
restored CREB activation to WT levels in YAC128 mice (right, one-way ANOVA
p = 0.015, KW stat = 8.3, direct comparison t tests shown).
(B) At four months, YAC128 mice learn the rotarod task significantly slower
than WT mice (left). Memantine-treated YAC128 mice exhibit significantly
improved motor learning versus untreated YAC128s (two-way ANOVA interac-
tion: WT versus YAC128 p = 0.029, F8,48 = 2.4, YAC128 versus YAC128-mem-
antine p = 0.0026, F8,48 = 3.6).
Data expressed as whisker box plot (A) and mean ± SEM (B).
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(Graham et al., 2006b; Shehadeh et al., 2006; Tang et al., 2005;
Zeron et al., 2002, 2004) and show increased NMDAR whole-cell
current and/or toxic signaling (Fan et al., 2007; Fernandes et al.,
2007; Zhang et al., 2008). In YAC128 MSNs, Ca2+ entry through
NMDARs leads to enhanced mitochondrial depolarization,
permeability transition, and consequently apoptosis (Fernandes
et al., 2007; Shehadeh et al., 2006). Notably, studies in neuronal
culture indicate that extrasynaptic NMDAR signaling triggers
mitochondrial membrane potential breakdown and cell death
(Hardingham et al., 2002; Leveille et al., 2008). Moreover, Leveille
et al. (2008) and others (Stanika et al., 2009) demonstrate that
high synaptic NMDAR activity does not produce cytosolic Ca2+
overload and produces no deleterious effects. It is likely that a
greater proportion of extrasynaptic NMDAR transmission results
in enhanced NMDA-induced toxicity in cultured YAC128 striatal
MSNs.
Relevance of Extrasynaptic Transmission to Signaling
Pathways Implicated in HD Pathogenesis
In brains from HD mice and human autopsy tissue, the neuronal
survival factor BDNF is reduced (Fusco et al., 2003; Reilly, 2001;
Zuccato et al., 2001, 2005), cysteine proteases known to cleave
htt and contribute to cell death are upregulated (Gafni and
Ellerby, 2002; Gafni et al., 2004; Goldberg et al., 1996; Wellington186 Neuron 65, 178–190, January 28, 2010 ª2010 Elsevier Inc.et al., 2002), mitochondria are dysfunctional, cellular energy
levels are low (Panov et al., 2002; Panov et al., 2005; Seong
et al., 2005), and gene transcription, particularly that mediated
by CREB, is dysregulated (Cha, 2007; Gines et al., 2003; Sugars
et al., 2004; Wyttenbach et al., 2001). Excessive extrasynaptic
NMDAR activity would be predicted to contribute to all of these
changes (Papadia and Hardingham, 2007).
In contrast to synaptic activity, extrasynaptic NMDAR sig-
naling triggers ‘‘cell death’’ transcriptional signaling by sup-
pressing phosphorylated (activated) CREB and failing to similarly
activate ERK in hippocampal cells (Hardingham et al., 2002; Lev-
eille et al., 2008). Indeed, we found that nuclear CREB activation
was reduced in both 1 month and 4 month YAC128 mouse stria-
tum, in agreement with a previous study showing reduced CREB
phosphorylation and BDNF transcription at early stages in
knockin HD mice (Gines et al., 2003). Strikingly, the reduction
in CREB activity, along with associated motor learning deficits,
found in YAC128 mice were reversed by treatment with a low
dose of memantine, previously shown to selectively inhibit
Ex-INMDA while preserving synaptic NMDAR current (Leveille
et al., 2008; Okamoto et al., 2009; Papadia et al., 2008). More-
over, Okamoto and colleagues (Okamoto et al., 2009) demon-
strated rescue of striatal volume loss and rotarod deficits at
12 months in YAC128 mice treated with low dose memantine,
whereas a 30-fold higher dose, which should inhibit both
synaptic and extrasynaptic NMDAR current, worsened the
phenotype and neurodegeneration in YAC128 mice. Together
with the results of that study, our observations at a very early,
presymptomatic age in YAC128 mice suggest a key role for
aberrant extrasynaptic NMDAR signaling in the onset of HD
behavioral, motor, and neurodegenerative phenotypes.
In addition to the link between enhanced Ex-INMDA and
reduced survival signaling via nuclear CREB activity in the
YAC128 striatum, we have also shown that altered NMDAR
localization and/or current is observed to a lesser extent in (1)
mice expressing fewer repeats (YAC72) and a milder HD pheno-
type and (2) in the YAC128 cortex, a brain region affected later
than the striatum in both human HD pathology (Vonsattel and
DiFiglia, 1998) and YAC128 mice (Cummings et al., 2009; Slow
et al., 2003). These data suggest that augmented extrasynaptic
NMDAR activity is specific to conditions that lead to HD patho-
genesis. Moreover, mhtt augmentation of Ex-INMDA was absent
in C6R mice that express full-length mhtt, but are protected
from the phenotypic and neuropathological effects of the trans-
gene. This finding provides a firm link between mhtt-induced
augmentation of Ex-INMDA signaling and HD pathogenesis and
suggests that mhtt cleavage and toxic fragment formation are
prerequisites for augmented Ex-INMDA (cell death signaling),
phenotype, and neuropathology in YAC128 mice.
Activation of Extrasynaptic NMDA Receptors
Although the physiological role of extrasynaptic NMDAR trans-
mission is debated, theories suggest that they constitute
a reserve pool for synaptic receptors or belong to a distinct
signaling pathway (reviewed in Ko¨hr, 2006; and Lau and Zukin,
2007). Stimulated activity, modeling endogenous activity pat-
terns, does activate extrasynaptic NR2B-containing NMDARs
in the hippocampus (Lozovaya et al., 2004) and perirhinal cortex
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cerebellar stellate cells that lack synaptic NMDARs, high stimu-
lation intensities or facilitated release, such as those employed
here, are required to activate perisynaptic NMDARs by spillover
(Carter and Regehr, 2000; Chen and Diamond, 2002; Clark and
Cull-Candy, 2002). The defining characteristics of striatal
MSNs include a low resting membrane potential and a high level
of excitatory input required to drive up-state transitions (pre-
dicted to be >1000 Hz) and action potential firing (Wilson and
Kawaguchi, 1996; Wolf et al., 2005). Such high activity levels
might render glutamatergic inputs to MSNs predisposed to spill-
over onto extrasynaptic sites, which may be pathological in
YAC128 MSNs due to increased receptor numbers.
In MSNs of the nucleus accumbens, extrasynaptic NMDAR
activity can also be driven by astrocytic glutamate release (D’As-
cenzo et al., 2007), dependent upon the activation of glial
mGluR5 receptors. As elevated extrasynaptic NMDAR activity
in YAC128 MSNs persisted when mGluRs were blocked, our
data suggest that this form of release was not engaged. How-
ever, as with YAC128 MSNs, extrasynaptic gliotransmission
was blocked by the NR2B-subunit-selective antagonist ifenpro-
dil (ibid). Thus, glial release is another candidate mechanism for
the physiological activation of elevated extrasynaptic NMDARs
in YAC128 MSNs. It follows that increased glutamate reuptake
would lessen the magnitude of extrasynaptic NMDAR activation.
Indeed, it has recently been shown that increasing glutamate
uptake in HD mice reduces the behavioral phenotype (Miller
et al., 2008). The question of how these receptors become acti-
vated in YAC128 MSNs will be the basis of future investigations.
Conclusions
Several studies have highlighted the adverse effects of extrasy-
naptic NMDAR signaling for neuronal viability in vitro (Gouix
et al., 2009; Hardingham et al., 2002; Leveille et al., 2008; Oka-
moto et al., 2009; Papadia et al., 2008), and we present a direct
link between an inherited neurodegenerative disease and
elevated extrasynaptic NMDAR transmission. Others have
shown that the clinically approved NMDAR antagonist meman-
tine, likely because of its unusual pharmacodynamics (Parsons
et al., 2007), specifically silences detrimental extrasynaptic
NMDAR activity, while leaving beneficial synaptic signaling unaf-
fected (Leveille et al., 2008; Okamoto et al., 2009; Papadia et al.,
2008). In addition to a previous report that memantine treatment
successfully reduced neuropathological and behavioral deficits
in HD mice at late stages (Okamoto et al., 2009), the study
presented here demonstrates that appropriate intervention
can delay early signaling and behavioral deficits in HD mice.
Thus, pharmacological mitigation of augmented extrasynaptic
NMDAR activity, along with drugs that boost glutamate uptake,
may delay onset and prevent progression of human HD.
EXPERIMENTAL PROCEDURES
Transgenic Mice and Brain Slice Preparation
YAC18, YAC72(2511), YAC128(55), C6R (W7 and W13), and YAC128(53)/WT
littermate mice (Graham et al., 2006a; Hodgson et al., 1999; Slow et al.,
2003) were maintained according to Canadian Council on Animal Care regula-
tions at the UBC Faculty of Medicine Animal Resource Unit. Acute coronal
slices were prepared for electrophysiological recording as in Milnerwoodand Raymond (2007). In mice aged >1 year, parasagittal slices were prepared
and the same striatal region targeted.
Electrophysiology
Basic methodology was as in Milnerwood and Raymond (2007). Standard arti-
ficial cerebrospinal fluid (aCSF) was identical excepting glycine (10 mM) and
strychnine (2 mM) were added to augment NMDAR activity and block glycine
receptors, respectively. Pipette resistance (Rp) was 3–6 MU when filled with
(in mM) 130 Cs methanesulfonate, 5 CsCl, 4 NaCl, 1 MgCl2, 5 EGTA, 10 HEPES,
5 QX-314, 0.5 GTP, 10 Na2-phosphocreatine, and 5 MgATP, pH 7.3, 290–295
mOsM. Tolerance for series resistance (Rs) was <20 MU and uncompensated;
DRs tolerance was <50% (mean change Rs = 10.2% ± 3.7%), providing Rs did
not exceed 30 MU. Results were confirmed by repeated analysis and offline Rs
compensation using AxographX. Recordings were made in 100 mM picrotoxin
(PTX) to block GABAA receptors, and further bath application of AMPA/kainate
receptor antagonist 10 mM 6-cyano-2,3-dihydroxy-7-nitro-quinoxaline
(CNQX), 10 or 30 mM GLT1/EAAT2 blocker DL-threo-b-Benzyloxyaspartic
acid (TBOA), and 50 mM NMDAR antagonist D-(-)-2-amino-5-phosphonopen-
tanoic acid (D-AP5) or 5 mM NMDAR antagonist (+/)-4-(trans)-2-carboxy-
5,7-dichloro-4-phenylaminocarbonylamino -1,2,3,4- tetrahydroquinoline
(L689,560) where stated (Tocris Bioscience, MO, USA). Signals were filtered
at 2 kHz, digitized at 10 kHz, and analyzed in Clampfit10 (Axon Instruments,
CA, USA).
sEPSCs were analyzed using Clampfit10 (threshold 8 pA). Individual cell
cumulative probabilities were plotted by genotype mean ± SEM. eEPSCs
were evoked by intrastriatal stimulation (100–200 ms) via micropipettes
(2–5 MU in aCSF) 150–200 mm dorsally. Concomitant field recording was per-
formed at the same depth, 50–100 mm, of the target cell. Evoked currents are
averages of three (0.066 Hz); kinetics expressed as Tau (t) or tau weighted (tW)
following Stocca and Vicini (1998).
INMDA was isolated by (1) dual AMPA and NMDA receptor-mediated currents
in modified aCSF (standard aCSF excepting: 5 mM Mg2+, 20 mM glycine, 2 mM
strychnine; ‘‘Low Mg2+’’), prior to D-AP5 or L689560 to produce subtracted
INMDA (Thomas et al., 2000); (2) in standard aCSF, cells were depolarized to
20 (sEPSCs) or +60 mV (eEPSCs) to relieve voltage-dependent Mg2+ block
prior to isolation by CNQX or D-AP5 block. After >3 min baseline, TBOA was
added and responses tracked for 5 or >10 min, prior to washout or AP5 addi-
tion. In addition to VC, IC recordings were conducted in aged mouse slices
using K+-gluconate ICS (129.4 K+-gluconate, 11.1 KCl, 4 NaCl, 0.02 EGTA,
10 HEPES, 0.3 GTP, and 3 MgATP, pH 7.3, 290–295 mOsM). Results are
mean ± SEM. Significance was tested in GraphPad Prism (La Jolla, CA, USA).
Golgi Impregnation and Cell Reconstruction
YAC18 (n = 4) and YAC128 (n = 4) mice were pentobarbital anesthetized then
perfused with 0.9% sucrose prior to Golgi-Cox impregnation (see Supple-
mental Experimental Procedures). MSNs were manually reconstructed (drawn
through340 z stacks) and spine densities calculated by visual identification of
spines in higher magnification overlays (3100 z stacks) using custom software
routines for Igor Pro (Wavemetrics; Lake Oswego, Oregon) designed in house
by J.D.B. as in Brown et al. (2007).
Electron Microscopy
Tissue for electron microscopy was harvested and prepared as in Hines et al.
(2008). For details, see Supplemental Experimental Procedures.
Tissue Preparation, Subcellular Fractionation, and Western Blot
Analyses
Subcellular fractionation was conducted on tissue from P23–P38 (YAC18,
29.5 ± 1.5 and YAC128, 31.2 ± 1.7) mice using an adapted protocol (Pacchioni
et al., 2009). Tissue was paired by day of dissection. Nuclear fractionation was
performed on tissue from 4-month-old brains. For details see Supplemental
Experimental Procedures.
Memantine Treatment
YAC128 mice (n = 10) and WT littermate mice (n = 4) were housed in identical
conditions. At 2 months, half the YAC128 mice (n = 5) were treated with
1 mg/kg memantine (Sigma) in drinking water (Okamoto et al., 2009). MiceNeuron 65, 178–190, January 28, 2010 ª2010 Elsevier Inc. 187
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Increased Extrasynaptic NMDARs in HD Micewere subjected to rotarod training (Van Raamsdonk et al., 2005) prior to perfu-
sion, then brains were microdissected and flash frozen prior to tissue prepara-
tion. For details, see Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at
doi:10.1016/j.neuron.2010.01.008.
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